Evaluation of COVID-19 Patients According to the Survival Time

Adem Atici, Ramazan Asoglu, Hasan Ali Barman, Mustafa Adem Tatlisu, Gönul Aciksari, Yusuf Yilmaz, Fatma Betul Ozcan, Mustafa Caliskan


Background: Coronavirus disease 2019 (COVID-19) was first detected as a form of atypical pneumonia. COVID-19 is a highly contagious virus, and some patients may experience acute respiratory distress syndrome (ARDS) and acute respiratory failure leading to death. We aim to evaluate the clinical, imaging, and laboratory parameters according to survival time to predict mortality in fatal COVID-19 patients. Methods: Fatal 350 and survived 150 COVID-19 patients were included in the study. Fatal patients were divided into three groups according to the median value of the survival days. Demographic characteristics and in-hospital complications were obtained from medical databases. Results: Of the non-survived patients, 30% (104) died within three days, 32% (110) died within 4-10 days, and 39% (136) died within over ten days. Pneumonia on computational tomography (CT), symptom duration before hospital admission (SDBHA), intensive care unit (ICU), hypertension (HT), C-reactive protein (CRP), D-dimer, multi-organ dysfunction syndrome (MODS), cardiac and acute kidney injury, left ventricular ejection fraction (LVEF), right ventricular fractional area change (RV-FAC), and Tocilizumab/Steroid therapy were independent predictors of mortality within three days compared to between 4-10 days and over ten days mortality.  A combined diagnosis model was evaluated for the age, CT score, SDBHA, hs-TnI, and D-dimer. The combined model had a higher area under the ROC curve (0.913). Conclusion: This study showed that age, pneumonia on CT, SDBHA, ICU, HT, CRP, d-dimer, cardiac injury, MODS, acute kidney injury, LVEF, and RV-FAC were independently associated with short-term mortality in non-surviving COVID-19 patients in the Turkish population. Moreover, Tocilizumab/Steroid therapy was a protective and independent predictor of mortality within three days.


COVID-19; mortality; acute respiratory distress syndrome; echocardiography


Chaolin Huang, Yeming Wang, Xingwang Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506.

World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. 2020;

Coronavirus Disease (COVID-19) Situation Reports [Internet]. [cited 2021 Jan 15]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

Nanshan Chen, Min Zhou, Xuan Dong, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–13.

Dawei Wang, Bo Hu, Chang Hu, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.

Yang F, Shi S, Zhu J, et al. Analysis of 92 deceased patients with COVID‐19. J Med Virol. 2020; 10.1002/jmv.25891.

Matt Arentz, Eric Yim, Lindy Klaff, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612–4.

Chaomin Wu, Xiaoyan Chen, Yanping Cai, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7): 1–11.

Xiaobo Yang, Yuan Yu, Jiqian Xu, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;475-81.

Zhaohai Zheng, Fang Peng, Buyun Xu , et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;e16-e25.

Fei Zhou, Ting Yu, Ronghui Du, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020;395:1054–62.

Barman Hasan Ali, Atici Adem, Sahin Irfan, et al. Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease. Coron Artery Dis. 2020;10.1097.

Li Yan, Hai-Tao Zhang, Jorge Goncalves, et al. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell. 2020;1–6.

Mikulska M, Nicolini LA, Signori A, et al. Tocilizumab and steroid treatment in patients with COVID-19. pneumonia. PLoS One. 2020;15(8):e0237831.

udadappanavar AM, Benni J. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. J Basic Clin Physiol Pharmacol. 2020;2191-0286.

Lara Bull-Otterson, Elizabeth B Gray, Daniel S Budnitz, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment—United States. Morb Mortal Wkly Rep. 2020;69(35):1210.

Feng Pan, Tianhe Ye, Peng Sun, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020;295:715–21.

Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, et al. and The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–69.

John A. Kellum, Norbert Lameire, Peter Aspelin, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.

Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J-Cardiovasc Imaging. 2015;16(3):233–71.

Prineas RJ, Crow RS, Zhang Z-M. The Minnesota code manual of electrocardiographic findings. Springer Science & Business Media; 2009.

Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol. 2004;37:81–90.

Das MK, Khan B, Jacob S, et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation. 2006;113(21):2495–501.

McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev. 2020;102537.

Tang N, Bai H, Chen X, et al . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.

Spadaro S, Fogagnolo A, Campo G, et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit Care. 2021;25(1):74.

D. Thomas-Rüddel, J. Winning, P. Dickmann, et al. Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. Anaesthesist. 2020;1–10.

Sufei Wang, Pei Ma, Shujing Zhang, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102–11.

Jiqian Xu, Xiaobo Yang, Luyu Yang, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care. 2020;24(1):1–11.

Carrillo-Vega MF, Salinas-Escudero G, Garcia-Peña C, et al. Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico. medRxiv. 2020; 20098145.

Celal Saticia Mustafa, Asim Demirkol, Elif Sargin, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. Int J Infect Dis. 2020;98:84–9.

Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. Eur J Intern Med. 2020;76:97–9.

Wenjie Tian, Wanlin Jiang, Jie Yao, et al. Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis. J Med Virol. 2020; 92:1875–1883.

Shaobo Shi, Mu Qin, Bo Shen, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;802-10.

Campo G, Contoli M, Fogagnolo A, et al. Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets. 2020:1-8.

Dominik Rath, Álvaro Petersen-Uribe, Alban Avdiu, et al. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. Clin Res Cardiol. 2020;1–9.

Omer Faruk Baycan, Hasan Ali Barman, Adem Atici, et al. Evaluation of biventricular function in patients with COVID-19 using speckle tracking echocardiography. Int J Cardiovasc Imaging. 2020;1–10.

Barman HA, Atici A, Tekin EA, et al. Echocardiographic features of patients with COVID-19 infection: a cross-sectional study. Int J Cardiovasc Imaging. 2021;37(3):825-34.

Pimentel SLG, Nascimento BR, Franco J, et al. Bedside echocardiography to predict mortality of COVID-19 patients beyond clinical data: Data from the PROVAR-COVID study. Rev Soc Bras Med Trop. 2021;54:e03822021.

Frattini S, Maccagni G, Italia L, Metra M, Danzi GB. Coronavirus disease 2019 and cardiovascular implications. J Cardiovasc Med. 2020;21(10):725–32.

Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol J Pathol Soc G B Irel. 2004;203(2):631–7.

He Yan, Shanshan Lu, Liangpei Chen, et al. Multiple organ injury on admission predicts in‐hospital mortality in patients with COVID‐19. J Med Virol.2020;1–13.

Jing Zhou, Lili Huang, Jin Chen, et al. Clinical features predicting mortality risk in older patients with COVID-19. Curr Med Res Opin. 2020;0(ja):1–1.

Jiatian Cao, Yan Zheng, Zhe Luo, et al. Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics. 2020;10(21):9663.

Marco Francone, Franco Iafrate, Giorgio Maria Masci, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;1–10.

Lingxi Guo, Dong Wei, Xinxin Zhang, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol. 2019;10:2752.

WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2022 Feb 24]. Available from: https://covid19.who.int

GISAID - hCov19 Variants [Internet]. [cited 2022 Feb 24]. Available from: https://www.gisaid.org/hcov19-variants/

Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44–57.

Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24.

Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet. 2021;398(10317):2126–8.

Pulliam JR, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. MedRxiv. 2021.

Sheikh A, Kerr S, Woolhouse M, et al. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: National cohort with nested test negative design study in Scotland. 2021.

Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance. 2021;26(50):2101147.

Khoury DS, Steain M, Triccas J, et al. Analysis: A meta-analysis of early results to predict vaccine efficacy against Omicron. medRxiv. 2021.

Barda N, Dagan N, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Reply. N Engl J Med. 2021;384(20):1970.

Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021;397(10287):1819–29.

Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21(6):395–404.

Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–84.

Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043–54.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.